Integra LifeSciences Holdings Corporation — Q1 2024 Form 10-Q
Business context and reporting period
Integra is a global medical technology company serving neurosurgery, surgical instrumentation, wound reconstruction, regenerative care, and related markets through two reportable segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). This filing covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $368.9 million | $380.8 million | Down $12.0 million, or 3.1% |
| Gross profit | $206.8 million | $232.9 million | Down $26.0 million |
| Gross margin | 56.1% | 61.1% | Down 500 basis points |
| Operating income | $4.0 million | $36.4 million | Down $32.4 million |
| Operating margin | 1.1% | 9.6% | Down 850 basis points |
| Net income/(loss) | $(3.3) million | $24.2 million | Declined $27.5 million |
| Diluted EPS | $(0.04) | $0.29 | Declined $0.33 |
| Operating cash flow | $15.8 million | $26.2 million | Down $10.4 million |
| Capital expenditures | $15.5 million | $13.7 million | Up $1.8 million |
CSS revenue increased 3.3% to $256.4 million, supported by mid-single-digit growth in the Neurosurgery portfolio, particularly Neuro Monitoring and CSF Management. TT revenue declined 15.3% to $112.4 million, primarily because of the Boston facility recall and weaker sales of Skin MediHoney and MicroMatrix.
Cash and cash equivalents were $591.9 million at March 31, 2024, compared with $276.4 million at December 31, 2023. Short-term investments were $71.2 million, and working capital was $1.11 billion. Total borrowings, excluding lease liabilities, were approximately $1.86 billion, consisting primarily of $1.19 billion under the Senior Credit Facility, $94.6 million under the securitization facility, and $571.0 million of convertible securities. The company was in compliance with its debt covenants.
Material changes versus the prior comparable period
- Revenue decreased 3.1%, driven mainly by an estimated $15.2 million impact from the Boston recall and a $2.4 million unfavorable foreign-exchange effect.
- Gross margin fell to 56.1% from 61.1%, primarily due to Boston idle-capacity costs and higher manufacturing expenses across the company’s facilities.
- Operating results included $30.2 million of special charges, compared with $24.5 million in Q1 2023. Q1 2024 charges included $7.0 million of Boston recall expenses, $12.0 million related to EU medical-device regulation, $6.5 million of structural optimization charges, and $4.7 million of acquisition, divestiture, and integration-related charges.
- The company recorded a $7.1 million impairment charge for a customer-relationship intangible asset associated with the Boston facility.
- Interest expense increased $1.5 million to $13.6 million because of incremental borrowings and higher interest rates.
- Operating cash flow declined as lower earnings, higher manufacturing costs, inventory growth, and reductions in certain current liabilities offset working-capital benefits from accounts receivable collections.
- Financing activities provided $358.7 million, including $370.5 million of new borrowings, compared with $162.7 million of financing cash outflows in Q1 2023, which included $150.0 million of share repurchases.
Guidance, outlook, risks, contingencies, and unusual items
Management stated that, following a March 2024 audit by an outside expert at the Boston facility, the company no longer expects to resume commercial distribution of products manufactured there during 2024. The company is assessing the additional remediation required. The Boston matter has affected product availability, revenue, manufacturing costs, intangible assets, and regulatory timelines, including the timing of potential SurgiMend approval.
On April 1, 2024, subsequent to the reporting date, Integra completed the acquisition of Acclarent from Johnson & Johnson for approximately $282.0 million in cash. The company drew on its revolving credit facility to help fund the transaction. Acclarent develops ENT medical devices and will be reported within CSS.
Other significant risks include FDA quality-system remediation, product recalls and potential additional regulatory action, supply-chain and manufacturing constraints, reimbursement and market-adoption risks, foreign-exchange and interest-rate volatility, acquisition integration, impairment of goodwill and intangible assets, and macroeconomic and geopolitical conditions.
Integra is defending an arbitration matter brought by Fortis Advisors concerning earnout consideration from the ACell acquisition and a securities class action concerning disclosures related to the Boston facility, remediation efforts, and Tissue Technologies forecasts. Management believes it has strong defenses, but the filing states that particular-period results, financial position, or cash flows could be materially affected by contingencies.
Management believes cash, available revolving credit, and other liquidity sources are sufficient to fund operations and capital expenditures for the next 12 months and the foreseeable future. The filing does not provide formal full-year revenue or earnings guidance.
Most important facts for investors to verify
- Progress, cost, and timing of FDA remediation and the expected restart of commercial distribution from the Boston facility.
- Whether Boston-related revenue losses, recall expenses, idle-capacity costs, and additional impairment charges continue through the remainder of 2024.
- Integration performance and financing impact of the Acclarent acquisition, including the resulting leverage and interest burden.
- Cash generation, inventory levels, and the company’s ability to service approximately $1.86 billion of borrowings, including the 2025 convertible notes maturity.
- Recovery or further deterioration in Tissue Technologies revenue and margins, and continued growth in CSS.
- Potential financial exposure from the ACell earnout arbitration, securities litigation, contingent consideration, and other legal or regulatory matters.
- Effect of foreign-exchange movements and higher SOFR-based borrowing costs, notwithstanding the company’s hedging programs.